Thu Sep 19 06:58:52 UTC 2024: ## Doximity Stock Sees Mixed Analyst Opinions, Insider Sales, and Institutional Interest
**New York, NY** – Doximity, Inc (NASDAQ: DOCS), a leading digital platform for medical professionals in the US, has been the subject of mixed opinions among analysts, with one firm, Baird R W, upgrading the stock to a “strong-buy” rating, while others like Wells Fargo & Company downgraded it to an “underweight” rating.
This mixed sentiment is reflected in the average analyst rating for the company, which currently sits at a “Hold,” with an average price target of $32.42. Despite this, Doximity exceeded analysts’ earnings expectations for the quarter ended August 8th, reporting $0.22 EPS compared to the projected $0.16.
In addition to the analyst activity, insider selling has also been a notable trend in recent months. Notably, CFO Anna Bryson sold 30,000 shares on August 9th, while Director Kira Scherer Wampler sold 2,500 shares on July 1st. These transactions, totaling $1,120,000.00 in value, have sparked some investor concern.
However, institutional investors remain confident in the company’s future, with 87.19% of Doximity’s stock currently held by institutions. Some hedge funds have even increased their holdings in recent quarters, including Blue Trust Inc. and First Horizon Advisors Inc., indicating strong belief in the company’s growth potential.
Doximity’s platform offers a wide range of tools designed to assist medical professionals, including collaboration, patient care coordination, virtual visits, access to medical news, and career management resources.
Despite the recent insider selling and mixed analyst opinions, Doximity’s strong financial performance and continued institutional support suggest a potentially bright future for the company. Investors will be closely watching the company’s performance in the coming months to see if it can sustain its growth trajectory and further solidify its position as a leading player in the digital healthcare space.
First Piper 